Clinical trial · no report yet · Phase 2
LUNAR
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
- NCT05496959 ↗
- Active not recruiting
- Jonsson Comprehensive Cancer Center
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- 177-Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (Lunar)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma; Recurrent Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Lutetium Lu-177 PNT2002; Quality-of-Life Assessment; Stereotactic Body Radiation Therapy
- Arms
- Arm 1 (SBRT) · Active comparator
- Arm 2 (177Lu-PNT2002, SBRT) · Experimental
- Enrollment
- 93
- Primary outcomes
- Prostate-specific membrane antigen positron emission tomography/computerized tomography (PSMA PET/CT)-based progression-free survival (PFS)
- Sponsor
- Jonsson Comprehensive Cancer Center with Eli Lilly and Company
- Start
- Sep 2, 2022
- Primary completion
- Sep 1, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT05496959 · updated May 26, 2026
Publications
linked from the registry- Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. 177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025 Dec 20;43(36):3812-3821. doi: 10.1200/JCO-25-01553. Epub 2025 Nov 12. PubMed 41223345